September 9, 2025

CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review…

September 8, 2025

CD73: a novel checkpoint protein STUTTGART, Germany I September 08, 2025 I La Merie Publishing announced the release of its…

September 5, 2025

IGF-1R: a validated thyroid eye disease target and a re-emerging cancer target – a pipeline review STUTTGART, Germany I September…

September 4, 2025

NaPi2b: a viable solid tumor target for novel ADC technologies – a pipeline review STUTTGART, Germany I September 04, 2025…

September 3, 2025

FcRn: a commercially and clinically validated target in a variety of antibody-mediated autoimmune diseases – a pipeline review STUTTGART, Germany…

September 1, 2025

New service: competitor analysis of targeted immunotherapies with targets selected by clients STUTTGART, Germany I September 01, 2025 I La…

August 31, 2025

KLK2: promising drug target in prostate cancer – a pipeline review STUTTGART, Germany I August 31, 2025 I La Merie…

August 30, 2025

Vectorized antibodies by in vivo expression of DNA or RNA overcome limitations of systemically administered antibodies STUTTGART, Germany I August…

August 30, 2025

STEAP1 and STEAP2: emerging prostate cancer targets – a pipeline review STUTTGART, Germany I August 30, 2025 I La Merie…

August 27, 2025

Tissue Factor: a validated target for improved solid tumor antibody-drug conjugates – a pipeline review STUTTGART, Germany I August 27,…